Affiliation:
1. Department of Orthopedics, People’s Hospital of Pan'an County, Zhejiang, China
2. Department of Orthopedics, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3. Department of Orthopedics, Hangzhou Lin'an Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China
Abstract
Objective Osteosarcoma and Ewing sarcoma of the rib, sternum, and clavicle are rare tumor entities, and their clinical features and treatment outcomes have been rarely reported. The present study was performed to evaluate their survival and confirm independent survival predictors. Methods Data on patients with osteosarcoma or Ewing sarcoma of the rib, sternum, and clavicle from 1973 to 2016 were retrospectively extracted from the database. Univariate and multivariate Cox regression analyses were used to determine the independent risk factors. Kaplan–Meier survival curves were applied to examine the prognostic difference between the groups. Results In total, 475 patients with osteosarcoma or Ewing sarcoma of the rib, sternum, and clavicle were eligible for this study, including 173 (36.4%) with osteosarcoma and 302 (63.6%) with Ewing sarcoma. The 5-year overall survival and cancer-specific survival rates of all patients were 53.6% and 60.8%, respectively. Six independent variables were identified, including age at diagnosis, sex, histological grade, metastatic status, tumor type, and surgery. Conclusions Surgical resection is a reliable treatment for osteosarcoma and Ewing sarcoma of the rib, sternum, and clavicle. Further research is needed to reconfirm the role of chemotherapy and radiotherapy in survival of these patients.
Funder
National Natural Science Foundation of China
China Postdoctoral Science Foundation
Natural Science Foundation of Zhejiang Province
Subject
Biochemistry (medical),Cell Biology,Biochemistry,General Medicine